Navigation Links
PharmaVentures Corporate Advisory Appoints Nikki Watkins as Practice Head, Product & Portfolio Strategy
Date:9/10/2009

OXFORD, England, September 10 /PRNewswire/ -- PharmaVentures announced today the appointment of Nikki Watkins as Head of the Product & Portfolio Strategy Practice of Corporate Advisory, leading a team of Senior Advisors and Analysts.

Fintan Walton, PhD, PharmaVentures' Chief Executive Officer says, "We are delighted to welcome Nikki to PharmaVentures. Our Corporate Advisory business is currently undergoing exciting developments, and extensive knowledge of portfolio assessment and strategy from GSK and PricewaterhouseCoopers will be a key contributor to our growth plans."

Tibor Papp, PhD, Head of Corporate Advisory Ltd, says, "Nikki brings substantial industry and advisory experience into PharmaVentures. She will take on a leadership role, further developing our practice in strategic analysis of products, companies and markets. With Nikki's experience, PharmaVentures further strengthens its leading position as shapers of the industry."

Nikki has an honours degree in Pharmacology from Cambridge University. Most recently, she was the Director of Portfolio Consolidation & Analysis, Global Product Strategy, R&D at GlaxoSmithKline (GSK).

Nikki brings additional industry experience to PharmaVentures from various previous roles in GSK R&D, commercial analysis, portfolio management and global internal audit. Prior to this, she qualified as a Chartered Accountant at PricewaterhouseCoopers.

Notes to Editors:

About PharmaVentures

A leading results driven organisation, PharmaVentures (http://www.pharmaventures.com) assists pharmaceutical and biotechnology companies across the world in all aspects of deal making and business intelligence. The Company provides tailored corporate advisory services to the Life Science industry, with additional deal making support provided through the PharmaDeals(R) range of intelligence products that include analysis tools and reports. An innovative business, PharmaVentures additionally provides industry insight through the world's first dedicated online pharmaceutical television channel http://www.pharmatelevision.com.

Now in its 17th year, PharmaVentures is based in Oxford, UK, employs over 50 people mostly educated to PhD or above, and has increased its turnover five fold with 80% of revenues from outside the UK. With offices in the USA and Australia, the Company works for a variety of clients from start-ups to global corporate pharmaceutical companies.

    PharmaTelevision(R) and PharmaDeals(R) are registered Trade Marks of
    PharmaVentures Ltd.

    For further information about PharmaVentures, please contact:

    Lisa Holloway, Marketing
    +44(0)1865-784-177
    lisa.holloway@pharmaventures.com


'/>"/>
SOURCE PharmaVenture
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. PharmaVentures Assists Helsinn in the Successful Sale of Helsinn Chemicals Ireland to the Medinco C.F.M. Group
2. Merck Engages PharmaVentures to Assist in the Divestment of its Italian Research Centre IRBM
3. Accuray Incorporated to Present at Robert Baird 2009 Healthcare Conference
4. Spherix Incorporated to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
5. Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update
6. SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2009 FINANCIAL RESULTS
7. Brookstone Pharmaceuticals Appoints New Corporate Position
8. OncoMed Pharmaceuticals Appoints Sunil Patel Senior Vice President, Corporate Development
9. ZyGEM Corp. Signs Agreement to Incorporate Its Breakthrough DNA Extraction Technology Into Rubicons Research and Diagnostic Products
10. Angiotechs corporate partner, Boston Scientific, announces launch of third-generation TAXUS(R) Element(TM) Stent
11. Cord Blood America to Hold Conference Call on Thursday May 21st at 11 a.m. Eastern Time to Discuss 2009 First Quarter Results and Corporate Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, ... second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical ... eBook by providing practical tips, tools, and strategies for clinical researchers. , “The ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... Lawrence, MA (PRWEB) , ... June 23, 2016 ... ... the Peel Plate® YM (Yeast and Mold) microbial test has received AOAC Research ... test platform of microbial tests introduced last year,” stated Bob Salter, Vice President ...
Breaking Biology Technology:
(Date:6/2/2016)... , June 2, 2016   The Weather Company ... announcing Watson Ads, an industry-first capability in which consumers will ... being able to ask questions via voice or text and ... Marketers have long sought an ... consumer, that can be personal, relevant and valuable; and can ...
(Date:5/24/2016)... care by providing unparalleled technology to leaders of the medical imaging industry.  As such, ... to the range of products distributed by Ampronix. Photo - http://photos.prnewswire.com/prnh/20160524/371420 ... ... ... With ...
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
Breaking Biology News(10 mins):